Klin Farmakol Farm. 2008;22(4):157-160

Hormone replacement therapy update

Tomáš Fait
Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze

Hormone replacement therapy with the lowest dosage, early start and individual approach is the first-choice drug for acute climacteric syndrome. It have been safety for cardiovascular disease so as for breast cancer in acceptance of contraindications. The early start of therapy is connected with lowering of cardiovascular risk in the sharp difference from later iniciation. Hormone replacement therapy should be given to the basic possition of osteoporosis prevention in connection with vitamine D and calcium intake. For therapy of urogenital atrophy we prefer the low-doses vaginal therapy. The rational and safety hormonal substitution are based on annualy discussion about risk/benefit ratio.

Keywords: Key word: hormone replacement therapy, acute climacteric disorders, atrophic vaginitis, osteoporosis, cardiovascular risk.

Published: January 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fait T. Hormone replacement therapy update. Klin Farmakol Farm. 2008;22(4):157-160.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Birkhäuser MH, Panay N, Archem DF, et al. Updated practical recommendations for HRT in the peri- and postmenopause. Climacteric 2008, 11: 108-123. Go to original source... Go to PubMed...
    2. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Indy 1999; 91, 13: 453-463. Go to original source... Go to PubMed...
    3. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy. Lancet, 1997; 350: 1047-1059. Go to original source...
    4. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. The Lancet 2002; 360: 942-944. Go to original source... Go to PubMed...
    5. Fait T, Šnajderová M, a kol. Estrogenní deficit, Maxdorf Jessenius, Prah 2007: 276.
    6. Simunic V, Banovic I, Ciglar S, et al. Local estrogen treatment in patients with urogenital symptoms, Gynecol Obstet 2003; 82: 187-197. Go to original source... Go to PubMed...
    7. Fait T. HT a osteoporóza - update 2007. Klimakterická medicína 2007; 12, 4: 7-8.
    8. Kim DK, Chancellor MB. Is estrogen for urinary incontinence good or bad? Review in Urology 2006; 8, 2: 91-92.
    9. Grodstein SR, Lifford K, Resnick NM, et al. Postmenopaual hormone therapy and risk of developing urinary incontinence. Obstet Gynecol 2004; 103: 254-260. Go to original source... Go to PubMed...
    10. WHI Steering Commitee: Effect of CEE in postmenopausal women. JAMA 2004; 291: 1701-1712. Go to original source... Go to PubMed...
    11. Fait T, Vrablík M. Změny lipidového spektra při užívání hormonální substituční terapie, Čas. lék. čes. 2004; 143, 2: 101-105.
    12. Fait T, Vrablík M, Zizka Z, Kostirova M. Changes in Haemostatic Variables Induced by Estrogen Replacement Therapy: Comparison of Transdermal and Oral Methods of Administration in Cross-over Designed Study, Gynecol Obstet Invest 2007; 65 (1): 47-51. Go to original source... Go to PubMed...
    13. Collins P, Beale CM. The cardioprotective role of HRT. Partheon London 1996, p. 60.
    14. Hulley S, Grady D, Bush M. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart desease in postmenopausal women, JAMA 280, 1998: 605-613. Go to original source... Go to PubMed...
    15. Grady D, Herrington D, Bittner V. Heart and estrogen/progestin replacement study follow-up (HERS II). Cardiovascular disease outcomes during 6-8 years of hormone therapy, JAMA 2002; 288: 49-57. Go to original source... Go to PubMed...
    16. WHI Steering Commitee: Effect of CEE in postmenopausal women. JAMA 2004; 291: 1701-1712. Go to original source... Go to PubMed...
    17. Hodis HN, Mack VJ, Lobo RA, et al. Estrogen in prevention of atherosclerosis. Ann Intern Med 2001; 135 (11): 939-953. Go to original source... Go to PubMed...
    18. Manson JE, Allison MA, Russouw JE, et al. Estrogen therapy and coronary-artefy calcification. N. Engl J Med 2007; 356: 2591-2602. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.